s a Greenwich, CT based private equity firm founded in
early 2005 by David S. Wetherell, founder and former CEO of CMGI and
innovator in the technology and Internet industries. GBP Capital's mission
is to improve the human condition by providing venture funding and
assistance to the most promising early to mid-stage life science companies.
GBP targets companies with novel approaches to diagnostics, therapeutics,
and medical devices that will change the face of healthcare innovation in
the future. For additional information, please visit the company's website
at
http://www.gbpcap.com .
About GBP IP, LLC
GBP IP, LLC is the privately held intellectual property affiliate of
GBP Capital.
Cell Genesys Forward-looking Statement
Statements made herein about the company, other than statements of
historical fact, including statements about the company's progress, results
and timing of clinical trials and preclinical programs and the nature of
product pipelines are forward-looking statements and are subject to a
number of uncertainties that could cause actual results to differ
materially from the statements made, including risks associated with the
success of clinical trials and research and development programs,
regulatory requirements and the regulatory approval process for clinical
trials, manufacture and commercialization of the company's products,
competitive technologies and products, patents, the need for and reliance
on partnerships with third parties, and the need for additional financings.
For information about these and other risks which may affect Cell Genesys,
please see the company's Annual Report on Form 10-K for the year ended
December 31, 2006 filed on March 1, 2007 as well as Cell Genesys' reports
on Form 10-Q and 8-K and other reports filed from time to time with the
Securities and Exchange Commission. The company assumes no obligation to
update the forward-looking information in t
'/>"/>
SOURCE Cell Genesys, Inc.; GBP IP, LLC Copyright©2007 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 Related biology technology :1.
Cell Genesys to Present at the Bear Stearns 20th Annual Healthcare Conference2.
Cell Genesys to Present at the BIO Investor Forum3.
Cell Genesys to Webcast Third Quarter 2007 Conference Call4.
Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients5.
YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 266.
Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering7.
BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.8.
Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets9.
China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results10.
Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain11.
Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter